Aqueous formulations for coating microneedle arrays

Patent metadata

Field	Value
Publication number	US-9693950-B2
Application number	US-201113699805-A
Country	US
Kind code	B2
Filing date	May 26, 2011
Priority date	May 28, 2010
Publication date	Jul 4, 2017
Grant date	Jul 4, 2017

Abstract

Aqueous formulations that include at least one active pharmaceutical ingredient; and at least one excipient, wherein the aqueous formulation has a viscosity of from 500 to 30,000 centipoise when measured at a shear rate of 100 s −1 and a temperature of 25° C.; a surface tension that is not greater than 60 dynes/cm when measured under ambient conditions; or a contact angle on a medical grade polymeric material of 50° or greater when measured under ambient conditions. Methods of coating and coated microneedle arrays using the aqueous formulations are also disclosed herein.

First claim

What is claimed is:

1. A method of forming a coated microneedle array comprising providing a microneedle array comprising a microneedle substrate and a plurality of microneedles;
providing a coating substrate;
providing an aqueous formulation comprising at least one active pharmaceutical ingredient and at least one excipient, wherein the aqueous formulation has a viscosity of from 500 to 30,000 centipoise when measured at a shear rate of 100 s −1 and a temperature of 25° C.;
applying the aqueous formulation to the coating substrate;
bringing the aqueous formulation and the microneedles of the microneedle array into contact with one another;
removing the microneedles from the aqueous formulation; and
allowing at least a portion of the aqueous formulation to evaporate,

wherein the aqueous formulation has a contact angle on a medical grade polymeric material of 50° or greater and 96° or less when measured under ambient conditions.

2. The method according to claim 1 , wherein the viscosity is from 500 to 10,000 centipoise when measured at a shear rate of 100 s −1 and a temperature of 25° C.

3. The method according to claim 1 , wherein the viscosity is from 500 to 8,000 centipoise when measured at a shear rate of 100 s −1 and a temperature of 25° C.

4. The method according to claim 1 , wherein the aqueous formulation has a contact angle on a medical grade polymeric material of 65° or greater and 96° C. or less when measured under ambient conditions.

5. A method of forming a coated microneedle array comprising
providing a microneedle array comprising a microneedle substrate and a plurality of microneedles;
providing a coating substrate;
providing an aqueous formulation comprising at least one active pharmaceutical ingredient and at least one excipient, wherein the aqueous formulation has a contact angle on a medical grade polymeric material of 50° or greater and 96° or less when measured under ambient conditions;
applying the aqueous formulation to the coating substrate;
bringing the aqueous formulation and the microneedles into contact with one another;
removing the microneedles from the aqueous formulation; and
allowing at least a portion of the aqueous formulation to evaporate.

6. The method according to claim 5 , wherein the aqueous formulation has a contact angle on a medical grade polymeric material of 65° or greater and 96° C. or less when measured under ambient conditions.

7. The method according to claim 1 , wherein the at least one active pharmaceutical ingredient is selected from vaccines, proteins, peptides, and polynucleotide sequences.

8. The method according to claim 1 , wherein the at least one excipient comprises a buffer selected from histidine, phosphate buffers, acetate buffers, citrate buffers, glycine buffers, ammonium acetate buffers, succinate buffers, pyrophosphate buffers, Tris acetate (TA) buffers, Tris buffers, saline solutions buffered with any of the above, or combinations thereof.

9. The method according to claim 1 , wherein the at least one excipient comprises sucrose, dextrins, dextrans, hyroxyethyl cellulose (HEC), polyvinyl pyrrolidone (PVP), polyethylene glycols, amino acids, polysorbate, human serum albumin, ethanol, sodium chloride, EDTA, saccharin sodium dehydrate, or combinations thereof.

10. The method according to claim 1 , wherein the active pharmaceutical ingredient is a vaccine and the aqueous formulation further comprises one or more adjuvants.

11. The method according to claim 1 , wherein the material comprising the microneedle array is selected from polycarbonate and liquid crystalline polymer.

12. The method according to claim 1 , wherein the coating substrate is at least a portion of a coating well.

13. The method according to claim 12 , wherein the coating well comprises a bottom surface and the microneedles contact the bottom surface of the coating well.

14. The method according to claim 1 , wherein the step of applying the aqueous formulation to the coating substrate comprises applying an excess of aqueous formulation to the coating substrate and adjusting the amount of aqueous formulation on the coating substrate.

15. The method according to claim 14 , wherein the step of adjusting the amount of aqueous formulation on the coating substrate comprises removing some aqueous formulation using an edge device.

16. The method according to claim 1 , wherein the step of bringing the aqueous formulation and the microneedles of the microneedle array into contact with one another is repeated at least once.

17. The method according to claim 1 , wherein the aqueous formulation has a surface tension that is from 40 and 55 dynes/cm when measured under ambient conditions.

Assignees

• Determan Amy S
• Johnson Peter R
• Moseman Joan T
• Woldt Ryan T
• Hansen Kristen J
• 3M Innovative Properties Co

Inventors

• Determan Amy S
• Johnson Peter R
• Moseman Joan T
• Woldt Ryan T
• Hansen Kristen J

Classifications

• A61K47/183

  Amino acids, e.g. glycine, EDTA or aspartame · CPC title

• A61K47/36

  Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin · CPC title

• A61K47/22

  Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones · CPC title

• A61K47/26

  Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin · CPC title

• A61K9/0021 Primary

  Intradermal administration, e.g. through microneedle arrays or needleless injectors · CPC title